Indivior's History

In 1994, Reckitt Benckiser Group plc (RB) established the Buprenorphine Business Group, marking the beginning of a journey that Indivior traces back more than 25 years. Following the demerger from RB in September 2014, Indivior PLC was established as an independent company and listed on the London Stock Exchange – ushering in the next chapter of our evolution. 

From our earliest days within RB, through the 2014 demerger, to who we are today, our focus has remained unwavering: meeting the needs of the people we serve. 

More than two decades ago, the treatment landscape for people living with opioid use disorder looked very different. Options were limited, access was constrained, and care was often confined to highly controlled clinical settings. Few medical professionals were able - or authorized - to treat OUD in an office‑based environment. 

Indivior helped change that reality. We played a leading role in advancing the recognition of opioid use disorder as a medical brain disease - one deserving of the same evidence‑based, compassionate approach as other conditions. Our work helped bring science‑driven treatment within reach, expanding access beyond traditional settings and enabling people living with OUD to receive care with greater flexibility, dignity, and privacy. 

We understood then, as we do now, that meaningful progress requires more than new treatment options - it requires a shift in mindset. By helping to reframe addiction as a medical condition, we worked to remove barriers, reduce stigma, and normalize care for people seeking recovery. 

We did this because we believe that recovery is possible, and that through science, purpose, and compassion, we can make a meaningful difference in the lives of people living with opioid use disorder.